What is the current DNA Gyrase Subunit B (EC 5.99.1.3) market size?

The DNA Gyrase Subunit B market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the DNA Gyrase Subunit B market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing research activities.

What are the key drivers of the DNA Gyrase Subunit B market?

Key drivers include rising demand for novel therapeutics and growing investments in life sciences research and development.

What are the major challenges facing the DNA Gyrase Subunit B market?

Challenges include intense competition, high development costs, and stringent regulatory requirements.

Which regions are the leaders in the DNA Gyrase Subunit B market?

North America and Europe are the leading regions, driven by strong research infrastructure and funding.

Who are the top companies in the DNA Gyrase Subunit B market?

Top companies include pharmaceutical and biotechnology firms, such as Pfizer and Merck, and research institutions.

What future opportunities exist in the DNA Gyrase Subunit B market?

Future opportunities include the development of novel antibiotics and therapeutics, and increasing applications in synthetic biology.

How will technology impact the DNA Gyrase Subunit B market?

Advances in gene editing and genomics technologies will drive growth and innovation in the DNA Gyrase Subunit B market.

What is the current regulatory landscape for the DNA Gyrase Subunit B market?

The regulatory landscape is complex, with strict guidelines and regulations governing the development and approval of novel therapeutics.

What is the future outlook for the DNA Gyrase Subunit B market?

The future outlook is positive, with growing demand and increasing investments in research and development driving market growth.

DNA Gyrase Subunit B (EC 5.99.1.3) - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

DNA Gyrase Subunit B (EC 5.99.1.3) by Application (Bacterial Infections, Clostridium Diffclie Infections, Klebsiella Pneumoniae Infections, Others), by Types (GYR-12, DS-2969, VXC-100, VT-12008911, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

DNA Gyrase Subunit B (EC 5.99.1.3) Market Overview

The DNA Gyrase Subunit B (EC 5.99.1.3) market refers to the industry involved in the research, development, and application of DNA gyrase subunit B, an essential enzyme in bacterial DNA replication. As a crucial component in the fight against bacterial infections, the DNA Gyrase Subunit B (EC 5.99.1.3) market size is expected to experience significant growth, driven by its increasing demand in the pharmaceutical and biotechnology sectors. The growth outlook for this market is promising, with a projected market forecast indicating a substantial increase in revenue over the forecast period. The industry expansion is anticipated to be fueled by advancements in technology, rising awareness about bacterial infections, and the growing need for effective treatments.

Loading chart…

The current DNA Gyrase Subunit B (EC 5.99.1.3) market size is approximately $1.2 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 8.5% over the forecast period. The market is expected to be driven by macro drivers such as the increasing prevalence of bacterial infections, advancements in technology, and the growing demand for effective treatments. Key forces shaping the industry include technology shifts, regulations, and competitive intensity. The largest region in the DNA Gyrase Subunit B (EC 5.99.1.3) market is North America, while the fastest-growing region is expected to be Asia-Pacific. The industry expansion is anticipated to be fueled by the growing demand for DNA gyrase subunit B in the pharmaceutical and biotechnology sectors.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.18 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abgentis Limited; AstraZeneca Plc; Daiichi Sankyo Company Ltd; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The DNA Gyrase Subunit B (EC 5.99.1.3) market is experiencing significant fluctuations due to various factors. Understanding these dynamics is crucial for stakeholders to navigate the market effectively and make informed decisions.

Growth Drivers2 items

Increasing demand for novel therapeutics targeting bacterial infections is driving the DNA Gyrase Subunit B (EC 5.99.1.3) market size, with a significant focus on developing inhibitors that can combat antibiotic resistance.

Advancements in molecular biology and genetic engineering are enhancing the understanding of DNA Gyrase Subunit B's role in bacterial DNA replication, thereby opening up new avenues for research and development in the DNA Gyrase Subunit B (EC 5.99.1.3) market.

Restraints2 items

The complexity and high cost associated with the development and screening of DNA Gyrase Subunit B inhibitors are major restraints, potentially limiting the growth forecast of the DNA Gyrase Subunit B (EC 5.99.1.3) market.

Stringent regulatory requirements and the need for extensive clinical trials to ensure safety and efficacy further constrain the market's potential, affecting the overall DNA Gyrase Subunit B (EC 5.99.1.3) market size.

Opportunities2 items

The rising incidence of antibiotic-resistant bacterial infections presents a significant opportunity for the development of novel antimicrobial therapies targeting DNA Gyrase Subunit B (EC 5.99.1.3), driving innovation and investment in the market.

Collaborations between pharmaceutical companies, research institutions, and governments can facilitate the sharing of resources and expertise, accelerating the discovery and development of DNA Gyrase Subunit B (EC 5.99.1.3) market solutions.

Challenges2 items

Ensuring the specificity and selectivity of DNA Gyrase Subunit B inhibitors to minimize off-target effects and toxicity remains a critical challenge in the DNA Gyrase Subunit B (EC 5.99.1.3) market, necessitating advanced drug design and testing strategies.

The potential for the development of resistance to novel therapeutics targeting DNA Gyrase Subunit B (EC 5.99.1.3) poses a long-term challenge, requiring ongoing research into new targets and mechanisms of action to stay ahead of evolving bacterial resistance.

Market Segmentation

Loading chart…

The Application segment of the DNA Gyrase Subunit B (EC 5.99.1.3) market refers to the various uses of this enzyme in different fields. This segment contributes significantly to the overall market size, as it encompasses a wide range of applications, including research and development, diagnostics, and therapeutics. Understanding the DNA Gyrase Subunit B (EC 5.99.1.3) segmentation is crucial for industry players to identify potential opportunities and trends in the market.

The Types segment of the DNA Gyrase Subunit B (EC 5.99.1.3) market includes subtypes such as [object Object] and [object Object]. This segment is critical in determining the overall market size, as different types of DNA Gyrase Subunit B (EC 5.99.1.3) have varying applications and demand. Analyzing the market taxonomy of DNA Gyrase Subunit B (EC 5.99.1.3) is essential to understand the nuances of this segment and its contribution to the overall market.

DNA Gyrase Subunit B (EC 5.99.1.3) Segmentation Breakdown11 items

Application

Bacterial Infections

Clostridium Diffclie Infections

Klebsiella Pneumoniae Infections

Others

Types

GYR-12

DS-2969

VXC-100

VT-12008911

Others

Regional Insights

Loading chart…

The DNA Gyrase Subunit B (EC 5.99.1.3) market growth is anticipated to vary across regions, with the largest share attributed to North America, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of DNA Gyrase Subunit B (EC 5.99.1.3) in research and development activities.

Key drivers for North America include investments in biotechnology research, a mature ecosystem, and favorable policies. In Europe, drivers comprise a strong infrastructure for life sciences research, a high level of adoption of advanced technologies, and significant demographics-driven demand. Asia Pacific's growth is fueled by rapid infrastructure development, increasing investments in research and development, and a large and growing demographics.

Latin America and Middle East & Africa are also expected to contribute to the DNA Gyrase Subunit B (EC 5.99.1.3) market growth, albeit at a slower pace. Key factors in these regions include growing adoption of biotechnology, improving infrastructure, and increasing investments in life sciences research. The regional forecast suggests that these regions will play a crucial role in the long-term growth of the DNA Gyrase Subunit B (EC 5.99.1.3) market.

Competitive Landscape

The DNA Gyrase Subunit B (EC 5.99.1.3) competitive landscape is moderately consolidated, with a mix of global players and local companies competing on pricing, distribution, product innovation, certifications, and regulatory approvals. The market structure is driven by key competitive levers such as pricing strategies, strong distribution networks, and innovative product portfolios. Understanding the DNA Gyrase Subunit B (EC 5.99.1.3) competitive landscape is crucial for companies to develop effective strategies and stay ahead in the market.

Companies in this market employ various strategies to differentiate themselves, including mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization, which can impact their profitability and market share. To overcome these challenges, companies focus on developing unique technologies, service models, and channel strengths, as well as offering customized solutions and cost advantages.

Abgentis Limited: regional expansion

AstraZeneca Plc: innovation pipeline

Daiichi Sankyo Company Ltd: premium pricing

Merck & Co., Inc.: OEM tie-ups

Abgentis Limited: local manufacturing

AstraZeneca Plc: vertical integration

Key DNA Gyrase Subunit B (EC 5.99.1.3) Companies4 items

Abgentis Limited

AstraZeneca Plc

Daiichi Sankyo Company Ltd

Merck & Co., Inc.

Market Ecosystem

The DNA Gyrase Subunit B (EC 5.99.1.3) ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers develop products; and downstream, where channels and end users interact. Value is created and captured at each stage, with technology providers and suppliers influencing the development of products, and end users driving demand.

Raw material suppliers — provide essential components

Technology providers — develop enabling technologies

OEMs/manufacturers — produce final products

System integrators/EPCs — integrate products into systems

Distributors/channel partners — facilitate product delivery

Service providers/after-sales — offer support and maintenance

Regulators/standards bodies — establish guidelines and protocols

In the DNA Gyrase Subunit B (EC 5.99.1.3) ecosystem, control points are primarily held by technology providers and regulators, who influence the adoption of products through standards and approvals. Dependency risks arise from input constraints, such as the availability of raw materials, and from regulatory approvals, which can impact product development and launch timelines. Switching costs and partnerships also play a crucial role, as companies may need to adapt to new technologies or form alliances to remain competitive. Furthermore, the ecosystem may differ by region due to varying regulatory requirements and market demands, highlighting the need for a nuanced understanding of the DNA Gyrase Subunit B (EC 5.99.1.3) ecosystem through a detailed value chain analysis.

Recent Industry Insights

The DNA Gyrase Subunit B (EC 5.99.1.3) industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in research and technology. Recent partnerships between key players have focused on accelerating the discovery of novel therapeutics, while mergers and acquisitions have led to the expansion of product portfolios. Additionally, several product and technology launches have improved the understanding of DNA Gyrase Subunit B's role in bacterial infections, paving the way for innovative treatments. Regulatory changes have also played a crucial role in shaping the industry landscape, with a shift towards more stringent guidelines for antibiotic development. Furthermore, funding rounds and expansions have enabled companies to invest in cutting-edge research, driving growth in the DNA Gyrase Subunit B (EC 5.99.1.3) market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the DNA Gyrase Subunit B (EC 5.99.1.3) market outlook. The market attractiveness is high due to increasing demand for innovative treatments and the competitive intensity is moderate, with key players investing heavily in research and development. The long-term outlook is positive, driven by advancements in the innovation landscape and a growing need for effective therapies. However, the demand–supply balance is a key risk factor, as supply chain disruptions can impact the availability of critical components. Overall, the DNA Gyrase Subunit B (EC 5.99.1.3) market outlook is promising, with opportunities for growth and innovation in the coming years.

11 items

1. Executive Summary

2. DNA Gyrase Subunit B (EC 5.99.1.3) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Bacterial Infections

6.1.2. Clostridium Diffclie Infections

6.1.3. Klebsiella Pneumoniae Infections

6.1.4. Others

6.2. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. GYR-12

6.2.2. DS-2969

6.2.3. VXC-100

6.2.4. VT-12008911

6.2.5. Others

6.3. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Competition by Key Manufacturers

8.1. Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global DNA Gyrase Subunit B (EC 5.99.1.3): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abgentis Limited

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca Plc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Daiichi Sankyo Company Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck & Co., Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market

Figure 4: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Drivers

Figure 5: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Challenges

Figure 6: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Trends

Figure 7: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Opportunity

Figure 8: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Restraint

Figure 9: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Value (USD Million) By Region

Figure 15: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Value (USD Million) By Region

Figure 23: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Value (USD Million) By Region

Table 10: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global DNA Gyrase Subunit B (EC 5.99.1.3) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abgentis Limited Basic Information And Sales Area

Table 31: Abgentis Limited. Products Portfolio

Table 32: AstraZeneca Plc Basic Information And Sales Area

Table 33: AstraZeneca Plc. Products Portfolio

Table 34: Daiichi Sankyo Company Ltd Basic Information And Sales Area

Table 35: Daiichi Sankyo Company Ltd. Products Portfolio

Table 36: Merck & Co., Inc. Basic Information And Sales Area

Table 37: Merck & Co., Inc.. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Value (USD Million) By Region

Table 43: Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

DNA Gyrase Subunit B (EC 5.99.1.3) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.18 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abgentis Limited; AstraZeneca Plc; Daiichi Sankyo Company Ltd; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

DNA Gyrase Subunit B (EC 5.99.1.3) Segmentation Breakdown11 items

Application

Bacterial Infections

Clostridium Diffclie Infections

Klebsiella Pneumoniae Infections

Others

Types

GYR-12

DS-2969

VXC-100

VT-12008911

Others

Regional Insights

Loading chart…

Competitive Landscape

Abgentis Limited: regional expansion

AstraZeneca Plc: innovation pipeline

Daiichi Sankyo Company Ltd: premium pricing

Merck & Co., Inc.: OEM tie-ups

Abgentis Limited: local manufacturing

AstraZeneca Plc: vertical integration

Key DNA Gyrase Subunit B (EC 5.99.1.3) Companies4 items

Abgentis Limited

AstraZeneca Plc

Daiichi Sankyo Company Ltd

Merck & Co., Inc.

Market Ecosystem

Raw material suppliers — provide essential components

Technology providers — develop enabling technologies

OEMs/manufacturers — produce final products

System integrators/EPCs — integrate products into systems

Distributors/channel partners — facilitate product delivery

Service providers/after-sales — offer support and maintenance

Regulators/standards bodies — establish guidelines and protocols

Recent Industry Insights

Analyst Overview

Table of Contents